Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.82 -1.3%	$0.85	$0.55 ▼ $1.66	$107.73M	0.92	1.34 million shs	684,773 shs
BHST BioHarvest Sciences	$7.69 +1.2%	$7.00	$4.66 ▼ $7.99	$124.83M	0.65	9,359 shs	816 shs
CLLS Cellectis	$2.95 +17.5%	$1.72	$1.10 ▼ $3.10	$139.51M	3.03	288,631 shs	432,032 shs
ENLV Enlivex Therapeutics	$1.45 -2.7%	$1.13	$0.81 ▼ $1.76	$35.24M	0.8	231,549 shs	250,283 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-1.32%	-2.01%	-1.68%	-3.79%	-39.04%
BHST BioHarvest Sciences	+1.18%	+1.45%	+12.76%	+17.76%	+768,999,900.00%
CLLS Cellectis	+17.53%	+17.06%	+78.79%	+85.42%	+33.48%
ENLV Enlivex Therapeutics	-2.68%	+29.23%	+28.32%	+39.42%	+8.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	2.6199 of 5 stars	3.7	4.0	0.0	0.0	2.0	1.7	0.0
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	2.5557 of 5 stars	3.5	3.0	0.0	0.0	2.5	2.5	0.0
ENLV Enlivex Therapeutics	2.1981 of 5 stars	3.7	3.0	0.0	0.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	649.29% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	77.72% Upside
CLLS Cellectis	3.00	Buy	$4.00	35.59% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	589.66% Upside

Current Analyst Ratings Breakdown

Latest ENLV, ATOS, CLLS, and BHST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
BHST BioHarvest Sciences	$27.70M	4.56	N/A	N/A	$0.08 per share	96.13
CLLS Cellectis	$49.22M	3.33	N/A	N/A	$2.36 per share	1.25
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
BHST BioHarvest Sciences	-$12.91M	-$0.50	N/A	N/A	N/A	-31.30%	-307.04%	-33.21%	8/14/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)

Latest ENLV, ATOS, CLLS, and BHST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CLLS Cellectis	-$0.15	N/A	N/A	N/A	$10.07 million	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
BHST BioHarvest Sciences	N/A	0.51	0.30
CLLS Cellectis	0.44	1.67	1.67
ENLV Enlivex Therapeutics	N/A	7.20	7.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
BHST BioHarvest Sciences	N/A
CLLS Cellectis	63.90%
ENLV Enlivex Therapeutics	1.02%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	7.60%
BHST BioHarvest Sciences	N/A
CLLS Cellectis	16.41%
ENLV Enlivex Therapeutics	12.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable

ENLV, ATOS, CLLS, and BHST Headlines

Recent News About These Companies

D. Boral Capital Reiterates "Buy" Rating for Enlivex Therapeutics (NASDAQ:ENLV)

July 31 at 3:49 AM | americanbankingnews.com

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025 | globenewswire.com

Enlivex Therapeutics' (ENLV) Buy Rating Reiterated at D. Boral Capital

July 24, 2025 | americanbankingnews.com

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 13, 2025 | usatoday.com

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona

June 11, 2025 | nasdaq.com

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

June 10, 2025 | globenewswire.com

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025 | globenewswire.com

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

April 23, 2025 | globenewswire.com

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial

April 23, 2025 | msn.com

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis

April 23, 2025 | nasdaq.com

Enlivex completed enrollment of patients in Phase II trial of Allocetra

April 22, 2025 | markets.businessinsider.com

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

April 21, 2025 | globenewswire.com

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?

April 7, 2025 | finance.yahoo.com

Enlivex Therapeutics doses first patient in Phase I trial of Allocetra

April 4, 2025 | markets.businessinsider.com

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

April 3, 2025 | globenewswire.com

Enlivex Therapeutics Releases 2024 Financial Statements

March 31, 2025 | tipranks.com

Enlivex Therapeutics price target raised to $7 from $6 at H.C. Wainwright

March 24, 2025 | markets.businessinsider.com

Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis

March 19, 2025 | nasdaq.com

Enlivex to receive Chinese patent for use of Allocetra as a potential treatment in patients with osteoarthritis

March 19, 2025 | pharmabiz.comP

Enlivex Therapeutics receives notice of allowance for Chinese patent

March 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
Kratos Defense Is Changing Warfare—Here’s What’s Driving It
By Jeffrey Neal Johnson | July 24, 2025
View Kratos Defense Is Changing Warfare—Here’s What’s Driving It

ENLV, ATOS, CLLS, and BHST Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.82 -0.01 (-1.32%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.83 +0.01 (+1.22%)

As of 08/1/2025 07:48 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

BioHarvest Sciences NASDAQ:BHST

$7.69 +0.09 (+1.18%)

As of 08/1/2025 03:43 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cellectis NASDAQ:CLLS

$2.95 +0.44 (+17.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.11 (+3.73%)

As of 08/1/2025 07:56 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Enlivex Therapeutics NASDAQ:ENLV

$1.45 -0.04 (-2.68%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.45 0.00 (0.00%)

As of 08/1/2025 07:53 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time